Place it in its market
Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.
See how Context works →On the price, the facts of the public record■Insider buy□Insider sell●Results filed
With an account, also○dividends▲splits◌next earningswith an account
End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.
Latest on record
The most recent facts, as filed.
Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.
- Oct 12, 2026Reported sale · Form 4Jarrad Mattieu Aguirre, Chief Medical Officer · $3.6KOpen the filing ↗
- Sep 10, 2026Reported sale · Form 4David Shook, Chief Medical Officer · $6.4KOpen the filing ↗
- Sep 10, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
In numbers
What this profile holds, counted.
Closes · 1 year250
SEC filings on record32815 flagged findings
Reported transactions (Form 4)80since Jun 14, 2024 · and 11 other holdings
Corporate events (8-K)27since Sep 30, 2021
What the record says
Description, identity and filings, each with its source.
Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.
Reverse splits in 5 years
1 reverse split in 5 years (1:20 on Jun 2, 2025) · 1:20 cumulative
The other times: of 818 securities that did their first reverse split in 5 years, a year later the median was worth 0.53× the price on the day of the split; 382 lost more than half and 209 rose (809 with a price a year later).
Our own series, not the whole market: based on the splits we have on record (provider and SEC); an unrecorded one does not count. Historical distribution, not a prediction.
The 25 most recent filings (of 328)
Every SEC filing, newest first, with what it is. Below, each type with its own explanation.
- Sep 10, 26Form 3 ↗Insider transaction
- Sep 10, 26Form 4 ↗Insider transaction
- Sep 10, 268-K ↗Current report · Other events
- Aug 14, 26SCHEDULE 13G/A ↗Passive stake · James B. Tananbaum · 2.7% · event on Jun 30, 26 · amendment
- Aug 6, 2610-Q ↗Quarterly report
- Aug 6, 268-K ↗Current report · Results
- Jul 17, 26CORRESP ↗Correspondence with the SEC
- Jul 17, 26Form 4 ↗Insider transaction
- Jul 16, 26UPLOAD ↗Correspondence with the SEC
- Jul 13, 26S-3 ↗Securities offering
- Jun 18, 26SCHEDULE 13G/A ↗Passive stake · Innovative Cellular Therapeutics Holdings Limited · 12.3% · event on May 18, 26 · amendment
328 filings on record, the oldest from May 7, 21.
Listing the 25 most recent filings of the 328 on record.
21114
- Mar 9, 26A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Nov 10, 25Entered a material agreement+3 more in the same filing8-K 1.01 ↗
- Nov 3, 25A senior executive left or was appointed8-K 5.02 ↗
- Sep 16, 25A senior executive left or was appointed8-K 5.02 ↗
- Jul 25, 25Entered a material agreement+3 more in the same filing8-K 1.01 ↗
- Jun 26, 25Sold unregistered shares8-K 3.02 ↗
- Jun 9, 25A senior executive left or was appointed8-K 5.02 ↗
- Apr 1, 25Restructuring plan with committed costs+2 more in the same filing8-K 2.05 ↗
- Jan 24, 25Listing notice (8-K 3.01)8-K 3.01 ↗
- Nov 26, 24A senior executive left or was appointed8-K 5.02 ↗
- Oct 31, 24Entered a material agreement+4 more in the same filing8-K 1.01 ↗
- Oct 24, 24Entered a material agreement+4 more in the same filing8-K 1.01 ↗
9 older filings not shown
Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.
Schedule 13G: short-form filing
The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.
- ARCH Venture Fund IX, L.P.13.9%Mar 31, 26SCHEDULE 13G/A ↗14 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
- Innovative Cellular Therapeutics Holdings Limited12.3%May 18, 26SCHEDULE 13G/A ↗
- Innovative Cellular Therapeutics Holdings Ltd9.8%Nov 6, 25SCHEDULE 13G ↗
- EULER FUND, L.P.6.7%Mar 6, 26SCHEDULE 13G ↗3 co-filers on this document — the figure is the largest single stake, not their sum.
- James Tananbaum6.7%Dec 31, 24SCHEDULE 13G/A ↗7 co-filers on this document — the figure is the largest single stake, not their sum.
show 6 more holdershide
- Explore Investments LLC6.6%Mar 31, 26SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
- Gates Frontier, LLC5.6%Jul 25, 25SCHEDULE 13G ↗2 co-filers on this document — the figure is the largest single stake, not their sum.
- BlackRock, Inc.4.5%Dec 31, 24SCHEDULE 13G/A ↗
- MWG Caph Ltd4.3%Mar 31, 26SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum.
- Newton (PTC) Limited3.9%Sep 30, 25SCHEDULE 13G/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum.
- James B. Tananbaum2.7%Jun 30, 26SCHEDULE 13G/A ↗7 co-filers on this document — the figure is the largest single stake, not their sum. · 2 earlier filings
Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.
- Oct 12, 26Sell$4KJarrad Mattieu AguirreChief Medical Officer↗
- Sep 10, 26Sell$6KDavid ShookChief Medical Officer↗
- Aug 21, 26Sell$149KLynn SeelyPresident and CEO↗
- Aug 21, 26Sell$15KStephen J. HillChief Operating Officer↗
- Aug 21, 26Sell$23KGary K. LeeChief Scientific Officer↗
- Aug 10, 26Sell$6KLynn SeelyPresident and CEO↗
- Aug 10, 26Sell$1KStephen J. HillChief Operating Officer↗
- Aug 10, 26Sell$2KGary K. LeeChief Scientific Officer↗
- Aug 10, 26Sell$9KVeronica Sanchez BulisVP, Corporate Controller↗
- Jul 17, 26Sell$137Innovative Cellular Therapeutics Holdings Ltd↗
- Jul 16, 26Sell$137Innovative Cellular Therapeutics Holdings Ltd↗
- Jun 10, 26Sell$25KDavid ShookChief Medical Officer↗
There are 20 more transactions in this stretch.
Stock compensation, tax and giftsshow the 8 other transactionshide
Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.
- Jul 27, 26Otheramount n/aInnovative Cellular Therapeutics Holdings Ltd↗
- Jul 27, 26Otheramount n/aInnovative Cellular Therapeutics Holdings Ltd↗
- Jun 29, 26Otheramount n/aInnovative Cellular Therapeutics Holdings Ltd↗
- Jun 15, 26Otheramount n/aInnovative Cellular Therapeutics Holdings Ltd↗
- Feb 10, 26Compensationamount n/aVeronica Sanchez BulisVP, Corporate Controller↗
- Feb 9, 26Compensationamount n/aLynn SeelyPresident and CEO↗
- Feb 9, 26Compensationamount n/aStephen J. HillChief Operating Officer↗
- Feb 9, 26Compensationamount n/aGary K. LeeChief Scientific Officer↗
The full record holds 72 transactions and goes back to Feb 24, 23.
Its sector and its market
Lyell Immunopharma, Inc. among Health Care companies
The profile shows what is on record. Context and Radar place the company among those of its sector and region.
Browse its neighbours
Other Health Care companies
With an account you also get
- The four engines — growth, trend, risk and context — each with its word and its score.
- The risk band and the sector phase.
- The company's fundamentals and accounts.
- Watchlist: your list of companies, with the «since you follow it» figure.
The research continues
The profile tells the story. The market sets the scene.
From Lyell Immunopharma, Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.
See what deserves a closer look
Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.
See how Radar works →Keep the why
Follow Lyell Immunopharma, Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.
See an example review →
Coverage
What sits behind this page.
Where each figure comes from and how far it reaches.
- Prices
- End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
- Series quality
- 250 clean closes in the period.
- SEC records
- 328 documents on file, from May 7, 2021 to Oct 13, 2026.
- Company description
- No description available.
- This page
- Generated on Oct 19, 2026; refreshed through the day.
Start at your own pace
Explore first. Go deeper with access.
Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.
Compare plans →- No account
This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.
- Pro
What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.
- Pro+
Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.
Are the prices real time?
No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.
Which SEC documents appear here?
Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.
Why does a European company show no SEC records?
It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.
Before forming a view on a company,
read what is on record.
One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.